Been diving into the Canadian AI stocks space lately and honestly, the opportunities here are pretty interesting. The global AI market hit nearly $200 billion in 2023 and is expected to balloon to almost $2 trillion by 2030 at a 36.6% annual growth rate. That's massive, and Canada's got some solid players in this game that most people sleep on.

Let me walk you through five smaller-cap Canadian AI stocks worth paying attention to. These weren't mega-caps, but they were doing real work in the AI space back in mid-2024.

Xtract One Technologies (TSX:XTRA) caught my eye first. Founded in 2016 with McMaster University backing, these guys built weapons detection and security tech using AI. They actually got the US Department of Homeland Security's SAFETY Act Designation, which is legit. After that, they landed contracts with MLB, NHL, and NBA teams. That's the kind of validation that matters.

Scope AI (CSE:SCPE) out of Vancouver is another one. They're using visual recognition and neural networks for enterprise growth, specifically targeting advertising. Their GEM system (general enterprise machine learning) handles ad tech with AI automation, fraud detection, and campaign optimization. They were actively expanding their team in 2024 to push the platform further.

OneSoft Solutions (TSXV:OSS) built cloud-based business solutions on Microsoft's platform. Their subsidiary OneBridge focuses on oil and gas pipeline operators using machine learning and data science. They signed a major multi-year deal with a South American operator in June 2024 to manage pipeline assets with their cognitive software platform.

Pivotree (TSXV:PVT) is interesting because they work with over 200 major retail and manufacturers globally. Their SKU Build system uses AI to cut time-to-market by 60% and costs by 75% compared to traditional methods. They also have Pivotree Dive, an ML platform for master data management optimization.

Last is Diagnos (TSXV:ADK), a healthcare tech firm focused on early disease detection. They use FLAIRE AI and Computer-assisted Retina Analysis to catch age-related macular degeneration, diabetic retinopathy, and hypertensive retinopathy. They were pushing for Health Canada and FDA approvals on new modules in 2024.

The thing about Canadian AI stocks in this space is they're solving real problems—security, commerce, healthcare, energy. Not just hype. If you're looking at the AI sector, these smaller-cap plays deserve a closer look. The sector's only going to grow from here.